发布文献求助

yyyyyyyyjt

Lv0

0 积分 2023-02-19 加入

最近求助
最近应助
互助留言

Immunity, Age, and Luminal Breast Cancer: Understanding the Holy Trinity 26天前 已完结
Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER) 27天前 已完结
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials 28天前 已完结
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer 1个月前 已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial 1个月前 已完结
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial 1个月前 已完结
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer 1个月前 已完结
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer 1个月前 已完结
Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial 1个月前 已关闭
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer 1个月前 已关闭

没有进行任何应助

最近帖子
最近评论

没有发布任何帖子

没有发布任何评论

Copyright © 2020-2026 AbleSci.COM, 科研通, All Right Reserved

科研通是非营利科研互助平台，不忘初心，为科研助力

本站互助的所有文件仅供个人学习研究用，禁止任何人把求助的所得文献进行盈利或传播

皖ICP备2024041134号-1

皖公网安备34019202002308

科研通【文献互助QQ群】：如果您有特殊求助，或发布求助超过24小时未得到应助，可加群求助，群号：821889395【点击一键加群】

科研通【志愿服务QQ群】：如果您热爱文献互助，有热心愿意为更多人服务，请加入小伙伴群，点击申请加入

关注微信服务号

科研通